PART I Item 1. B usiness. Overview We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities. Our suite of gene editing technologies is anchored by our proprietary base editing te...
Q2 FY2026 — expected 2026-08-03
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001193125-26-065194 | EDGAR | 141K words |
| 2025-02-25 | 2024-12-31 | 0000950170-25-026076 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0000950170-24-020622 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0000950170-23-004866 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0000950170-22-002166 | EDGAR | — |
| 2021-03-15 | 2020-12-31 | 0001564590-21-013190 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001564590-20-014308 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001193125-25-263542 | EDGAR | 35K words |
| 2025-08-05 | 2025-06-30 | 0000950170-25-102393 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-063966 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0000950170-24-121104 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091242 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0000950170-24-053939 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-060683 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039364 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0000950170-23-020090 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022322 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-015755 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0000950170-22-008238 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-05 | 0001193125-26-093914 | EDGAR | 1K words |
| 2026-02-24 | 0001193125-26-065191 | EDGAR | — |
| 2026-02-12 | 0001193125-26-048684 | EDGAR | — |
| 2026-02-05 | 0001193125-26-039365 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009722 | EDGAR | — |
| 2025-12-11 | 0001193125-25-316043 | EDGAR | — |
| 2025-11-04 | 0001193125-25-263536 | EDGAR | — |
| 2025-08-05 | 0000950170-25-102389 | EDGAR | — |
| 2025-07-03 | 0000950170-25-093906 | EDGAR | — |
| 2025-06-06 | 0000950170-25-083043 | EDGAR | — |
107 total filings indexed. 78 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001745999 |
| Ticker | BEAM |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.beamtx.com |
| Listed | 2020-02-06 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report